PortalPublikationenHepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hep...

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes

Standard

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. / Tham, Christine Y L; Kah, Janine; Tan, Anthony T; Volz, Tassilo; Chia, Adeline; Giersch, Katja; Ladiges, Yvonne; Loglio, Alessandro; Borghi, Marta; Sureau, Camille; Lampertico, Pietro; Lütgehetmann, Marc; Dandri-Petersen, Maura; Bertoletti, Antonio.

in: CELL REP MED, Jahrgang 1, Nr. 4, 21.07.2020, S. 100060.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tham, CYL, Kah, J, Tan, AT, Volz, T, Chia, A, Giersch, K, Ladiges, Y, Loglio, A, Borghi, M, Sureau, C, Lampertico, P, Lütgehetmann, M, Dandri-Petersen, M & Bertoletti, A 2020, 'Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes', CELL REP MED, Jg. 1, Nr. 4, S. 100060. https://doi.org/10.1016/j.xcrm.2020.100060

APA

Tham, C. Y. L., Kah, J., Tan, A. T., Volz, T., Chia, A., Giersch, K., Ladiges, Y., Loglio, A., Borghi, M., Sureau, C., Lampertico, P., Lütgehetmann, M., Dandri-Petersen, M., & Bertoletti, A. (2020). Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. CELL REP MED, 1(4), 100060. https://doi.org/10.1016/j.xcrm.2020.100060

Vancouver

Tham CYL, Kah J, Tan AT, Volz T, Chia A, Giersch K et al. Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. CELL REP MED. 2020 Jul 21;1(4):100060. https://doi.org/10.1016/j.xcrm.2020.100060

Bibtex

@article{2ee445ab20944e9380e9f1134aea904a,
title = "Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes",
abstract = "Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) to complete its infection cycle and causes severe hepatitis, with limited therapeutic options. To determine the prospect of T cell therapy in HBV/HDV co-infection, we study the impact of HDV on viral antigen processing and presentation. Using in vitro models of HBV/HDV co-infection, we demonstrate that HDV boosts HBV epitope presentation, both in HBV/HDV co-infected and neighboring mono-HBV-infected cells through the upregulation of the antigen processing pathway mediated by IFN-β/λ. Liver biopsies of HBV/HDV patients confirm this upregulation. We then validate in vitro and in a HBV/HDV preclinical mouse model that HDV infection increases the anti-HBV efficacy of T cells with engineered T cell receptors. Thus, by unveiling the effect of HDV on HBV antigen presentation, we provide a framework to better understand HBV/HDV immune pathology, and advocate the utilization of engineered HBV-specific T cells as a potential treatment for HBV/HDV co-infection.",
author = "Tham, {Christine Y L} and Janine Kah and Tan, {Anthony T} and Tassilo Volz and Adeline Chia and Katja Giersch and Yvonne Ladiges and Alessandro Loglio and Marta Borghi and Camille Sureau and Pietro Lampertico and Marc L{\"u}tgehetmann and Maura Dandri-Petersen and Antonio Bertoletti",
note = "{\textcopyright} 2020 The Authors.",
year = "2020",
month = jul,
day = "21",
doi = "10.1016/j.xcrm.2020.100060",
language = "English",
volume = "1",
pages = "100060",
journal = "CELL REP MED",
issn = "2666-3791",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes

AU - Tham, Christine Y L

AU - Kah, Janine

AU - Tan, Anthony T

AU - Volz, Tassilo

AU - Chia, Adeline

AU - Giersch, Katja

AU - Ladiges, Yvonne

AU - Loglio, Alessandro

AU - Borghi, Marta

AU - Sureau, Camille

AU - Lampertico, Pietro

AU - Lütgehetmann, Marc

AU - Dandri-Petersen, Maura

AU - Bertoletti, Antonio

N1 - © 2020 The Authors.

PY - 2020/7/21

Y1 - 2020/7/21

N2 - Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) to complete its infection cycle and causes severe hepatitis, with limited therapeutic options. To determine the prospect of T cell therapy in HBV/HDV co-infection, we study the impact of HDV on viral antigen processing and presentation. Using in vitro models of HBV/HDV co-infection, we demonstrate that HDV boosts HBV epitope presentation, both in HBV/HDV co-infected and neighboring mono-HBV-infected cells through the upregulation of the antigen processing pathway mediated by IFN-β/λ. Liver biopsies of HBV/HDV patients confirm this upregulation. We then validate in vitro and in a HBV/HDV preclinical mouse model that HDV infection increases the anti-HBV efficacy of T cells with engineered T cell receptors. Thus, by unveiling the effect of HDV on HBV antigen presentation, we provide a framework to better understand HBV/HDV immune pathology, and advocate the utilization of engineered HBV-specific T cells as a potential treatment for HBV/HDV co-infection.

AB - Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) to complete its infection cycle and causes severe hepatitis, with limited therapeutic options. To determine the prospect of T cell therapy in HBV/HDV co-infection, we study the impact of HDV on viral antigen processing and presentation. Using in vitro models of HBV/HDV co-infection, we demonstrate that HDV boosts HBV epitope presentation, both in HBV/HDV co-infected and neighboring mono-HBV-infected cells through the upregulation of the antigen processing pathway mediated by IFN-β/λ. Liver biopsies of HBV/HDV patients confirm this upregulation. We then validate in vitro and in a HBV/HDV preclinical mouse model that HDV infection increases the anti-HBV efficacy of T cells with engineered T cell receptors. Thus, by unveiling the effect of HDV on HBV antigen presentation, we provide a framework to better understand HBV/HDV immune pathology, and advocate the utilization of engineered HBV-specific T cells as a potential treatment for HBV/HDV co-infection.

U2 - 10.1016/j.xcrm.2020.100060

DO - 10.1016/j.xcrm.2020.100060

M3 - SCORING: Journal article

C2 - 33205065

VL - 1

SP - 100060

JO - CELL REP MED

JF - CELL REP MED

SN - 2666-3791

IS - 4

ER -